Generic Name: acalabrutinib (a KAL a BROO ti nib)
Brand Name: Calquence
What is acalabrutinib?
Acalabrutinib blocks the action of certain enzymes in the body, which can interfere with the growth and spread of cancer cells.
Acalabrutinib was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, patients responded to this medicine. However, further studies are needed.
Acalabrutinib may also be used for purposes not listed in this medication guide.
This medicine can make it easier for you to bleed. Contact your doctor or seek emergency medical attention if you have any bleeding that will not stop.
Call your doctor at once if you have signs of bleeding inside your body, such as: dizziness, weakness, confusion, headache, speech problems, black or bloody stools, pink or brown urine, or coughing up blood or vomit that looks like coffee grounds.
Before taking this medicine
You should not use acalabrutinib if you are allergic to it.
To make sure acalabrutinib is safe for you, tell your doctor if you have ever had:
an active or chronic infection;
a heart rhythm disorder;
bleeding problems; or
hepatitis B (acalabrutinib can cause this condition to come back or get worse).
Taking acalabrutinib may increase your risk of developing other types of cancer, such as skin cancer. Talk to your doctor about this risk and what skin symptoms to watch for.
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It is not known whether acalabrutinib passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using acalabrutinib, and for at least 2 weeks after your last dose.
How should I take acalabrutinib?
Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Acalabrutinib is usually taken once every 12 hours until your body no longer responds to the medicine.
Take this medicine with a full glass of water.
You may take acalabrutinib with or without food.
Do not chew, break, or open the acalabrutinib capsule. Swallow it whole.
If you need surgery, tell the surgeon ahead of time that you are using acalabrutinib. You may need to stop using the medicine for a short time.
While using acalabrutinib, you may need frequent blood tests.
Store at room temperature away from moisture and heat.
What happens if I miss a dose?
Take the missed dose as soon as you remember. If you are more than 3 hours late, skip the missed dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while taking acalabrutinib?
If you also take an antacid or stomach acid reducer (such as Zantac), take your acalabrutinib dose at least 2 hours before you take the stomach medicine.
Acalabrutinib side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
unusual bleeding (nose, mouth, vagina, or rectum), or any bleeding that will not stop;
signs of bleeding inside your body--dizziness, weakness, confusion, problems with speech, prolonged headache, black or bloody stools, pink or brown urine, or coughing up blood or vomit that looks like coffee grounds;
low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet;
signs of a serious brain infection--any change in your mental state, decreased vision, weakness on one side of your body, or problems with walking (may start gradually and get worse quickly).
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
Acalabrutinib dosing information
Usual Adult Dose for Lymphoma:
100 mg orally approximately every 12 hours
Duration of Therapy: Until disease progression or unacceptable toxicity
Comments: The indication for this drug is approved under accelerated approval based on overall response rate; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
Use: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
What other drugs will affect acalabrutinib?
Many drugs can interact with acalabrutinib. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any you start or stop using, especially:
an antibiotic or antifungal medicine;
heart medication; or
This list is not complete and many other drugs can interact with acalabrutinib. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.
More about acalabrutinib
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: multikinase inhibitors
Other brands: Calquence
Related treatment guides
Where can I get more information?
- Your pharmacist can provide more information about acalabrutinib.
- Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
- Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2012 Cerner Multum, Inc. Version: 1.01.
Last reviewed: November 02, 2017
Date modified: January 03, 2018